Items where authors include "Bowcock, S"

Article

Coulson, AB, Royle, K-L orcid.org/0000-0003-0225-1199, Pawlyn, C et al. (22 more authors) (2022) Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial. BMJ Open, 12 (6). e056147. ISSN 2044-6055

Ramasamy, K, Sadler, R, Jeans, S et al. (17 more authors) (2022) Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T cell response. British Journal of Haematology, 197 (3). pp. 293-301. ISSN 0007-1048

Ramasamy, K, Sadler, R, Jeans, S et al. (15 more authors) (2022) COVID symptoms, testing, shielding impact on patient-reported outcomes and early vaccine responses in individuals with multiple myeloma. British Journal of Haematology, 196 (1). pp. 95-98. ISSN 0007-1048

Drayson, MT, Bowcock, S, Planche, T et al. (23 more authors) (2019) Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. The Lancet Oncology, 20 (12). pp. 1760-1772. ISSN 1470-2045

Drayson, MT, Bowcock, S, Planche, T et al. (13 more authors) (2019) Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT. Health Technology Assessment, 23 (62). pp. 1-94. ISSN 1366-5278

Conference or Workshop Item

Cook, G, Pawlyn, C, Royle, K-L et al. (20 more authors) (2021) Fitness, a UK Myeloma Research Alliance (UK-MRA) Frailty-Adjusted Therapy Study, Supports the Feasibility of Recruiting Frail Newly Diagnosed Myeloma Patients to Large Clinical Trials. In: 63rd American Society of Hematology Annual Meeting, 11-14 Dec 2021, Atlanta, Georgia, USA.